Plain-English translation of NCT05086692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which is designed to help your immune system recognize and attack cancer cells more effectively. is a specially engineered form of a protein that activates your body's cancer-fighting immune cells while avoiding the cells that suppress immunity. The medication is being tested both on its own and in combination with another existing immunotherapy drug called pembrolizumab.
An older version of this type of medication has been used for cancer, but it had significant side effects and required frequent dosing. This medication is designed to work better, last longer in your body, and have fewer unwanted effects, which could make it a more practical and tolerable option for patients with advanced cancers.
You likely qualify if…
You likely don't qualify if…
You will receive either alone or combined with pembrolizumab at a clinical research site, depending on which group you are assigned to. You will have regular CT or MRI scans approximately every 8 weeks to monitor how your tumor is responding to the treatment. The study is conducted in multiple phases, starting with dose-finding followed by expansion to test the best doses in specific cancer types, and you can withdraw from the study at any time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States